HCA

HCA Healthcare, Inc. - Q1 2002 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2002. HCA Inc. is a holding company owning and operating 175 hospitals and 74 freestanding surgery centers across 23 U.S. states, England, and Switzerland. The company operates through Eastern, Western, and National geographic groups, with a primary focus on core urban markets.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 8.3% year-over-year, driven by an 8.8% increase in revenue per equivalent admission. This was primarily due to favorable managed care contract renewals and improved government reimbursement rates.
• Profitability: Income before taxes rose 15.5% to $626 million. Reported net income increased 18.1% to $385 million. Adjusted net income (excluding goodwill amortization) increased 12.4%.
• Expense Trends:
  • Salaries and Benefits: Increased 8.3% to $1,930 million, remaining flat at 39.6% of revenue.
  • Supplies: Increased 9.4% to $778 million, rising to 16.0% of revenue due to higher pharmaceutical and orthopedic costs.
  • Bad Debts: Provision for doubtful accounts rose to 7.6% of revenue (from 7.2%) due to rate increases on self-pay and uninsured patients.
  • Interest Expense: Decreased 14.8% to $121 million, aided by lower LIBOR rates and improved credit ratings.
• Volume: Total admissions declined 1.1% due to a light flu season and fewer business days, though same-facility admissions increased 0.9%.

Outlook, Risks, and Contingencies

• Government Investigations: HCA remains subject to ongoing federal investigations (DOJ, SEC) and qui tam actions regarding billing practices, cost reports, and physician relations. A $250 million settlement with CMS regarding Medicare cost reports was announced in March 2002 (accrued in 2001) but requires DOJ approval.
• Legal Proceedings: Significant litigation includes consolidated qui tam actions, shareholder derivative suits, and class actions alleging billing fraud. Management states ultimate liability cannot be reasonably estimated but could materially affect financial position.
• Tax Disputes: The IRS is claiming an additional $313 million in taxes and interest for prior years. Management believes recorded provisions are adequate.
• Liquidity and Capital: Operating cash flow improved significantly ($609 million). The company has a $2.5 billion credit facility with approximately $1.5 billion available. Capital expenditures for 2002 are projected at $1.6 billion.
• Market Risk: Approximately $1.9 billion of long-term debt is variable-rate. A hypothetical 1% interest rate increase would reduce pretax earnings by approximately $19 million annually.

Investor Verification Checklist

• Verify the status of the $250 million CMS settlement and whether DOJ approval has been obtained.
• Monitor the outcome of the consolidated qui tam actions and shareholder derivative suits (e.g., Morse and McCall cases) for potential material liabilities.
• Review the resolution of the $313 million IRS tax dispute.
• Assess the impact of rising supply costs (pharmaceuticals, orthopedics) on future operating margins.
• Confirm the company's compliance with the Corporate Integrity Agreement (CIA) and any new regulatory requirements.